ArticleBMC genomics2014
Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease.
Article in BMC genomics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- Diagnostic value of LncRNA SNHG16 for osteoporotic fractures and its potential regulation of fracture healing.Hereditas · 2025Article
- Bleeding and Thrombosis in Multiple Myeloma: Platelets as Key Players during Cell Interactions and Potential Use as Drug Delivery Systems.International journal of molecular sciences · 2023Review
- Using Proteomics Data to Identify Personalized Treatments in Multiple Myeloma: A Machine Learning Approach.International journal of molecular sciences · 2023Article
- Proteomic Alteration in the Progression of Multiple Myeloma: A Comprehensive Review.Diagnostics (Basel, Switzerland) · 2023Review
- An atlas of the bone marrow bone proteome in patients with dysproteinemias.Blood cancer journal · 2023Article
- An atlas of the bone marrow bone proteome in patients with dysproteinemias.Research square · 2023Article
- Protein Digestion for 2D-DIGE Analysis.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Clinical Proteomics: Liquid Chromatography-Mass Spectrometry (LC-MS) Purification Systems.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Identification and clinical validation of EMT-associated prognostic features based on hepatocellular carcinoma.Cancer cell international · 2021Article
- Liquid biopsy: an evolving paradigm for the biological characterisation of plasma cell disorders.Leukemia · 2021Review
- Protective Effects of Vitamin K Compounds on the Proteomic Profile of Osteoblasts under Oxidative Stress Conditions.Molecules (Basel, Switzerland) · 2020Article
- Proteomics-inspired precision medicine for treating and understanding multiple myeloma.Expert review of precision medicine and drug development · 2020Article
- Rapid discrimination of multiple myeloma patients by artificial neural networks coupled with mass spectrometry of peripheral blood plasma.Scientific reports · 2019Article
- Variability of serum novel serum peptide biomarkers correlates with the disease states of multiple myeloma.Clinical proteomics · 2019Article
- Differential expression of serum proteins in multiple myeloma.Experimental and therapeutic medicine · 2019Article
- Development and characterisation of a panel of phosphatidylinositide 3-kinase - mammalian target of rapamycin inhibitor resistant lung cancer cell lines.Scientific reports · 2018Article
- Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients.BBA clinical · 2017Article
- Proteomic profiling of mdx-4cv serum reveals highly elevated levels of the inflammation-induced plasma marker haptoglobin in muscular dystrophy.International journal of molecular medicine · 2017Article
- Proteomic analysis of bronchoalveolar lavage fluid (BALF) from lung cancer patients using label-free mass spectrometry.BBA clinical · 2017Article
- Towards Stratified Medicine in Plasma Cell Myeloma.International journal of molecular sciences · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBone destruction is a feature of multiple myeloma, characterised by osteolytic bone destruction due to increased osteoclast activity and suppressed or absent osteoblast activity. Almost all multiple myeloma patients develop osteolytic bone lesions associated with severe and debilitating bone pain, pathologic fractures, hypercalcemia, and spinal cord compression, as well as increased mortality. Biomarkers of bone remodelling are used to identify disease characteristics that can help select the optimal management of patients. However, more accurate biomarkers are needed to effectively mirror the dynamics of bone disease activity.
resultsA label-free mass spectrometry-based strategy was employed for discovery phase analysis of fractionated patient serum samples associated with no or high bone disease. A number of proteins were identified which were statistically significantly correlated with bone disease, including enzymes, extracellular matrix glycoproteins, and components of the complement system.
conclusionsEnzyme-linked immunosorbent assay of complement C4 and serum paraoxonase/arylesterase 1 indicated that these proteins were associated with high bone disease in a larger independent cohort of patient samples. These biomolecules may therefore be clinically useful in assessing the extent of bone disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.